Mit Ixchiq von Valneva steht erstmals ein Vakzin gegen das Chikungunya-Virus zur Verfügung. Der Lebendimpfstoff ist zur ...

Im vergangenen Jahr wurde der erste Chikungunya-Impfstoff zugelassen, ein attenuierter Lebendimpfstoff. Nun genehmigte die EU ...

Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics. The French pharma company ...

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...

The Danish company’s chikungunya vaccine, Vimkunya, has now crossed the FDA finish line, heating up the competition with Valneva by countering with a label that covers a broader population.

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older The European Commission (EC) will now review ...

Die Diskussion dreht sich hauptsächlich um den Impfstoff IXCHIQ von Valneva gegen das Chikungunya-Virus und die Aktienentwicklung des Unternehmens. Ein Nutzer erwähnt eine bevorstehende CHMP ...

H.C. Wainwright lowered the firm’s price target on Valneva (VALN) to $17 from $18 and keeps a Buy rating on the shares following the Q4 report. The firm cites reduced sales estimates for Ixchiq ...

Ratings for Valneva VALN were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...